加速動脈硬化家兎モデル: 内腸骨動脈バルーン傷害の方法論的視点

Executive Industry Relevance

The rabbit iliac artery balloon injury model accelerates atherosclerotic plaque development, enabling rapid assessment of therapeutic interventions within a two-week timeframe. This approach supports target validation and mechanistic de-risking in cardiovascular drug discovery by providing a reproducible, disease-relevant system that mimics human coronary pathology. The model enhances predictive confidence in preclinical studies by delivering quantifiable morphometric and angiographic endpoints for evaluating drug efficacy and safety.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by inducing controlled endothelial injury and lipid accumulation in a clinically relevant arterial bed.
• Operational Value: Provides a standardized, reproducible method for generating consistent atherosclerotic lesions to support target engagement studies.
• Strategic Value: Accelerates target validation timelines, allowing rapid go/no-go decisions based on plaque morphology and biomarker expression.

Screening & Assay Development

• Scientific Value: Generates quantifiable plaque metrics such as intima-media thickness, lipid area, and macrophage infiltration for assay readout standardization.
• Operational Value: Delivers high-success-rate lesion formation with low mortality, supporting scalable screening campaigns.
• Strategic Value: Facilitates assay readiness for evaluating drug effects on plaque stabilization, inflammation, and lipid accumulation.

Translational & Preclinical Research

• Scientific Value: Offers a disease-relevant system with human-like plaque composition, including smooth muscle cell proliferation and macrophage-derived foam cells.
• Operational Value: Enables longitudinal monitoring of plaque progression via morphometric quantification at defined intervals (e.g., two and four weeks).
• Strategic Value: Supports translational biomarker alignment by correlating lesion characteristics with therapeutic response.

Pipeline & Workflow Integration

The model fits within the cardiovascular discovery continuum, supporting early target validation through to preclinical efficacy assessment by providing a rapid, quantifiable atherosclerosis model.

• Discovery Biology: Supports hypothesis testing of atherogenic pathways via inducible, time-dependent plaque formation in the iliac artery.
• Screening: Enables standardized compound evaluation through reproducible lesion development and measurable endpoints like lumen area reduction and intimal thickening.
• Analytics: Provides morphometric and angiographic outputs (e.g., plaque area, lipid accumulation) that allow objective comparison across treatment groups.
• Translational Research: Connects to preclinical validation by modeling human coronary-like pathology and enabling assessment of device or drug effects on plaque composition.
• Enterprise Reuse: Establishes a reusable platform for iterative testing of cardiovascular therapeutics across multiple projects.

Operational & Enterprise Impact

• Scientific Value: Delivers mechanistic insight into plaque development pathways, reducing ambiguity in target validation.
• Operational Value: Ensures reproducibility and standardization through defined surgical and dietary protocols with high success rates.
• Strategic Value: Improves capital efficiency by accelerating preclinical timelines and reducing late-stage failure risk through early biological de-risking.
• Portfolio Impact: Enables risk-adjusted prioritization of candidates based on plaque-modifying effects and safety profiles.

Implementation Considerations

• Requires expertise in rodent vascular surgery, anesthesia, and postoperative care.
• Dependent on access to balloon catheters, surgical platforms, and imaging or histology infrastructure for endpoint analysis.
• Necessitates standardization across teams for consistent injury length, diet duration, and tissue processing.
• Adaptation considerations include species-specific lipid metabolism and differences in plaque composition compared to human disease.
• Practical limitations include the two-week induction window, which may not capture chronic plaque complexity or calcification seen in advanced human atherosclerosis.

Biopharma FAQs